Argenica Therapeutics Ltd Ordinary Shares AGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.13
- Day Range
- A$0.13–0.13
- 52-Week Range
- A$0.09–0.35
- Bid/Ask
- A$0.12 / A$0.15
- Shares Outstanding
- 128.46M
- Market Cap
- A$16.06M
- Volume/Avg
- 8,213 / 141,027
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.02%
Company Profile
Argenica Therapeutics Ltd is a clinical-stage biotechnology company engaged in the research and development of novel neuroprotective therapeutics. Its lead drug candidate, ARG-007 (xaranetide), is being developed to reduce brain tissue damage following stroke and other acute neurological injuries. The company has completed a Phase 2 clinical trial of xaranetide in acute ischaemic stroke patients and is advancing preparations for a late-stage clinical trial. It also conducts preclinical and non-clinical studies to evaluate xaranetide in other neurological conditions, including traumatic brain injury and concussion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.argenica.com.au
Valuation
|
Metric
|
AGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.72 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AGN
|
|---|---|
Quick Ratio | 10.51 |
Current Ratio | 10.60 |
Interest Coverage | −5,038.55 |
Quick Ratio
AGN
Profitability
|
Metric
|
AGN
|
|---|---|
Return on Assets (Normalized) | −17.55% |
Return on Equity (Normalized) | −24.09% |
Return on Invested Capital (Normalized) | −27.92% |
Return on Assets
AGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|s#L!rr | LOCK|V><y@ | $129B | |||
| Moderna Inc
MRNA
| LOCK|@p%>^Vg | LOCK|#tf | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@RJrHL | LOCK|Nv&^ | $79B | |||
| argenx SE ADR
ARGX
| LOCK|&$!^XQ& | LOCK|^<M | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<&#j%xR | LOCK|bk^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fqqyVH | LOCK|K#$$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Hh<&^Q%n | LOCK|b!^?w | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|$RnQ%k | LOCK|%Rz | $24B | |||
| Incyte Corp
INCY
| LOCK|H<@##fN | LOCK|!r | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|dMd@pfk | LOCK|W^D | $14B |
United States